• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
CHEN Si,MI Xianwei,SHI Jing.Analysis of formulation similarity requirements for biowaiver of bioequivalence studies in multi-strength fixed-dose combinations by the European Medicines Agency[J].Journal Of Pharmaceutical Research,2025,44(9):877-881[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2196times   Download 782次 QR Code for this article
Scan with your phone!
欧洲药品管理局对于多规格复方制剂生物等效性试验豁免的处方相似性要求解析
陈思,米贤伟,石靖
Font:Larger+|Default|Smaller-
(国家药品监督管理局药品审评中心,北京 100022)
摘要:
本文基于欧洲药品管理局(EMA)2010年发布的《生物等效性研究指南》(Rev.1版本)及2020年至2021年发布的临床药理学与药代动力学问答文件(Q&A)中第6.4和6.5部分,系统解析了EMA对于多规格化学药品复方制剂基于已通过生物等效性(BE)试验的规格,对其他规格申请BE豁免的处方相似性要求,为国内复方制剂研发与注册提供科学参考。
关键词:  欧洲药品管理局  多规格复方制剂  生物等效性试验豁免  处方相似性
DOI:10.13506/j.cnki.jpr.2025.09.008
基金项目:
Publication Date:September 25, 2025
Analysis of formulation similarity requirements for biowaiver of bioequivalence studies in multi-strength fixed-dose combinations by the European Medicines Agency
CHEN Si,MI Xianwei,SHI Jing
(Center for Drug Evaluation,National Medical Products Administration,Beijing 100022,China)
Abstract:
This article systematically analyzes the European Medicines Agency (EMA)'s requirements for formulation similarity when applying for bioequivalence (BE) waivers for other specifications of multi-specification chemical compound pharmaceutical preparations, based on specifications that have already passed BE trials. The analysis is conducted in accordance with Investigation of bioequivalence - Scientific guideline (Rev.1, 2010) and Clinical pharmacology and pharmacokinetics: questions and answers (Sections 6.4 and 6.5, 2020—2021) issued by EMA. The findings aim to provide scientific references for the development and registration of FDCs in domestic markets.
Key words:  EMA  Multi-strength fixed-dose combinations  Biowaiver of bioequivalence studies  Formulation similarity requirements
Today's Visits:485    Total Visits:2383197
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.